Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

• Published in: Toxicological sciences
• Main Authors: Li, Jinjin, Wu, Wentong, Chen, Jiajia, Xu, Zhifei, Yang, Bo, He, Qiaojun, Yang, Xiaochun, Yan, Hao, Luo, Peihua
• Format: Journal Article
• Language: English
• Published: United States 08.10.2024
• Subjects: Inhibitors; Management; RAS; Toxicity; Mechanism
• ISSN: 1096-6080; 1096-0929; 1096-0929
• DOI: 10.1093/toxsci/kfae129

The RAS gene family holds a central position in controlling key cellular activities such as migration, survival, metabolism, and other vital biological processes. The activation of RAS signaling cascades is instrumental in the development of various cancers. Although several RAS inhibitors have gained approval from the United States Food and Drug Administration (FDA) for their substantial antitumor effects, their widespread and severe adverse reactions significantly curtail their practical usage in the clinic. Thus, there exists a pressing need for a comprehensive understanding of these adverse events, ensuring the clinical safety of RAS inhibitors through the establishment of precise management guidelines, suitable intermittent dosing schedules, and innovative combination regimens. This review centers on the evolution of RAS inhibitors in cancer therapy, delving into the common adverse effects associated with these inhibitors, their underlying mechanisms, and the potential strategies for mitigation.